DPP-4 inhibitors and angioedema: a cause for concern?

被引：16
|
作者：
Byrd, Jennifer S. [2 ]
Minor, Deborah S. [1 ]
Elsayed, Raghda [3 ]
Marshall, Gallen D.
机构：
[1] Univ Mississippi, Med Ctr, Dept Med, Div Gen Internal Med Hypertens, Jackson, MS 39216 USA
[2] Univ Mississippi, Med Ctr, Dept Pharm, Jackson, MS 39216 USA
[3] Providence Med Grp, Portland, OR USA
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2011年 / 106卷 / 05期
关键词：
DIPEPTIDYL PEPTIDASE-IV; RISK; SITAGLIPTIN; BRADYKININ; EFFICACY; EDEMA;
D O I：
10.1016/j.anai.2011.02.012
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：436 / 438
页数：3
相关论文
共 50 条
  • [1] Some DPP-4 inhibitors may increase risk of angioedema
    Reactions Weekly, 2022, 1919 (1) : 12 - 12
  • [2] DPP-4 inhibitors
    Ahren, Bo
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 21 (04) : 517 - 533
  • [3] DPP-4 inhibitors may cause severe joint pain
    Reactions Weekly, 2015, 1568 (1) : 2 - 2
  • [4] DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
    Eun Ju Bae
    Archives of Pharmacal Research, 2016, 39 : 1114 - 1128
  • [5] DPP-4 Inhibitors and the Occurrence of Infections
    Willemen, M. J. C.
    Mantel-Teeuwisse, A. K.
    Straus, S. M. J. M.
    Egberts, A. C. G.
    Leufkens, H. G. M.
    DRUG SAFETY, 2010, 33 (10) : 937 - 937
  • [6] DPP-4 inhibitors and atherosclerosis: The promise
    Jialal, Ishwarlal
    Bajaj, Mandeep
    ATHEROSCLEROSIS, 2013, 227 (02) : 224 - 225
  • [7] Bullous pemphigoid with DPP-4 inhibitors
    Reactions Weekly, 2019, 1745 (1) : 1 - 1
  • [8] Renoprotective Effects of DPP-4 Inhibitors
    Kawanami, Daiji
    Takashi, Yuichi
    Takahashi, Hiroyuki
    Motonaga, Ryoko
    Tanabe, Makito
    ANTIOXIDANTS, 2021, 10 (02) : 1 - 17
  • [9] Pharmacoeconomic analysis of DPP-4 inhibitors
    Teramachi, H.
    Ohta, H.
    Tachi, T.
    Toyoshima, M.
    Mizui, T.
    Goto, C.
    Tsuchiya, T.
    PHARMAZIE, 2013, 68 (11): : 909 - 915
  • [10] DPP-4 inhibitors: focus on safety
    Tella, Sri Harsha
    Rendell, Marc S.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (01) : 127 - 140
12345